UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 12, 2009
|
(Exact name of registrant as specified in its charter) |
| | |
| | |
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
| | |
995 E. Arques Avenue, Sunnyvale, California | |
(Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: (408) 774-0330
|
(Former name or former address, if changed since last report.) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
On November 12, 2009, Pharmacyclics, Inc. a Delaware corporation (the "Registrant"), announced that posters related to PCI-24781 and PCI 32765 have been selected for presentation at the 51st Annual Meeting of the American Society of Hematology (ASH), December 5-8, 2009 in New Orleans, Louisiana.
The foregoing description is qualified in its entirety by reference to the Registrant's Press Release dated November 12, 2009, a copy of which is attached hereto as Exhibit 99.1 and incorporated herein by reference.
Item 9.01. | Financial Statements and Exhibits. |
| (d) Exhibits. | | |
| | | |
| Exhibit No. | | Description |
| | | |
| 99.1 | | Press Release of Pharmacyclics, Inc. dated November 12, 2009. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.
| PHARMACYCLICS, INC. | |
| | | |
November 12, 2009 | By: | /s/ Robert W. Duggan | |
| | Name: Robert W. Duggan | |
| | Title: Chairman and CEO | |